BACKGROUNDPrognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown to improve patients' outcomes in first-line settings.METHODSWe conducted a retrospective, multicenter study, including HNSCC that...
-
May 25, 2021 (v1)Journal articleUploaded on: December 4, 2022
-
May 25, 2021 (v1)Journal article
Abstract BACKGROUND Prognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown to improve patients' outcomes in first‐line settings. METHODS We conducted a retrospective, multicenter study, including...
Uploaded on: September 12, 2024 -
August 2024 (v1)Journal article
Background: Trifluridine/tipiracil (FTD/TPI) is approved in third-line treatment of patients with advanced/metastatic gastric and gastroesophageal junction adenocarcinomas (aGA/GEJA). The association of oxaliplatin with FTD/TPI is promising and the combination of FTD/TPI + oxaliplatin + nivolumab has shown a predictable and manageable safety...
Uploaded on: January 13, 2025